galecto.com Open in urlscan Pro
35.214.210.212  Public Scan

Form analysis
0 forms found in the DOM

Text Content

 * Welcome
 * About
   * Board
   * Management
   * Founders
   * Clinical Advisory Boards
     * IPF
     * Liver cirrhosis
     * Oncology
     * Myelofibrosis
   * Presentations
 * Diseases
   * Fibrosis
   * Cancer
   * Literature
   * Scientific Conferences
 * Pipeline
 * Investors
   * News & Events
   * Scientific Conferences
   * Stock Information
   * Corporate Governance
   * Financials & Filings
   * IR Resources
 * Careers
 * Contact
 * Menu Menu


 * 


OUR FOCUS

Galecto is a clinical stage biotechnology company committed to the development
of novel small molecule therapeutics directed at biological targets which are at
the heart of fibrosis, inflammation, and cancer.

Galecto was founded by leading fibrosis-focused scientists and biotech
executives and is built on more than 10 years of research into galectin and
fibrosis modulators. Our team has developed a deep understanding of the galectin
family of proteins and the LOXL2 enzyme, and how both influence multiple
biological pathways of these complex, often devastating, diseases.




OUR SCIENCE

Galecto’s goal is to develop a portfolio of drugs that target biochemical
pathways common to the development of fibrosis with the intent of bringing
therapeutic benefit to patients suffering from a broad range of fibrotic
diseases. We are developing small molecule fibrosis inhibitors focusing on two
targets: galectin-3 and LOXL2.

Galectin-3 has been implicated in diseases of the lung, liver, eye and
cardiovascular system amongst many others, where it can promote the development
of tissue scarring (fibrosis) and inflammation. In addition, galectin expression
and activity has been associated with the development and progression of cancer,
often with a poor prognosis.

LOXL2, a key enzyme involved in the formation of the extracellular matrix during
the fibrotic process, has been implicated in multiple fibrotic indications,
including myelofibrosis and fibrotic diseases of the lung, liver and kidney.




FIBROSIS


CANCER


INFLAMMATION

Diseases we fight

Galecto’s founders have pioneered the scientific exploration of galectin biology
and chemistry.

Hans SchambyeCEO

Galectins represent a promising new drug-target. Galecto’s modulators may open
up new treatment possibilities for many severe diseases.

Hakon LefflerProfessor, Lund University, Department of Laboratory Medicine

Galectin-3 plays a key role in fibrosis development and Galecto’s inhibitors are
able to potently block this effect, and may thus lend new hope to patients
suffering from fibrosis.

Tariq Sethi
PreviousNext

Galecto, Inc. develops small molecules for the treatment of severe diseases,
including fibrosis and cancer. The company, founded in 2011, builds on more than
10 years of research centering on the role of galectin-3 and LOXL-2, and the use
of modulators of these proteins to treat fibrosis-related diseases and cancer.
Combined with a strong patent estate, these assets give Galecto a unique
therapeutic platform.




FOLLOW US


Board

Management

Founders

Copyright Galecto, Inc 2020 © 
CookiesPrivacy Policy
Scroll to top

This website uses cookies to improve your experience. We'll assume you're ok
with this, but you can opt-out if you wish
OK Reject Read More
Privacy & Cookies Policy
Close

PRIVACY OVERVIEW

This website uses cookies to improve your experience while you navigate through
the website. Out of these, the cookies that are categorized as necessary are
stored on your browser as they are essential for the working of basic
functionalities of the ...
Necessary
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly.
This category only includes cookies that ensures basic functionalities and
security features of the website. These cookies do not store any personal
information.
Non-necessary
Non-necessary
Any cookies that may not be particularly necessary for the website to function
and is used specifically to collect user personal data via analytics, ads, other
embedded contents are termed as non-necessary cookies. It is mandatory to
procure user consent prior to running these cookies on your website.
SAVE & ACCEPT